Application of CoQ10 in silicosis fibrosis resistance

A technology for pulmonary fibrosis and lung tissue, applied in the field of medical engineering, can solve problems such as pulmonary fibrosis, no specific treatment plan, excessive deposition of pulmonary interstitial collagen, etc.

Pending Publication Date: 2019-09-06
NINGXIA MEDICAL UNIV
View PDF0 Cites 1 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, when the lung tissue is repeatedly or overly stimulated, fibroblasts proliferate abnormally and secrete a large number of collagen fibers, resulting in excessive deposition of collagen in the lung interstitium, and fibrosis of the lung interstitium thickening
Clinical treatment mainly focuses on bronchoalveolar lavage combined with anti-fibrosis and symptomatic treatment of complications. At the same time, comprehensive treatment strategies such as oxygen therapy and psychological counseling are given, but there is no specific treatment plan. Therefore, whether it can be excavated from the treasure trove of existing drugs New drugs that are safer, more convenient, and have multiple advantages in prevention and treatment are of great significance for reducing symptoms of patients and reducing social burdens

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of CoQ10 in silicosis fibrosis resistance
  • Application of CoQ10 in silicosis fibrosis resistance
  • Application of CoQ10 in silicosis fibrosis resistance

Examples

Experimental program
Comparison scheme
Effect test

Embodiment Construction

[0022] The reagent involved in the present invention is as follows: SiO 2 (Sigma Company, batch number 14808-60-7); Coenzyme Q10 (Soleibao Company, batch number: 303-98-0); Corn oil (Aladdin, batch number 8001-30-7); Sirius red kit was purchased at ( LEAGENE, batch number 0402A19); HE staining kit; hydroxyproline kit (alkaline hydrolysis) (Nanjing Jiancheng Institute of Biological Products, batch number: A030-2); α-SMA rabbit source primary antibody (Chengdu Zhengneng Company, Product number: 347277); HMGCR mouse primary antibody (SANTA company, product number Sc-271595); mouse two-step detection kit (mouse enhanced polymer detection system) (Zhongshan Jinqiao, product number: PV-9002); rabbit Two-step detection kit (rabbit enhanced polymer detection system) (Zhongshan Jinqiao, Cat. No.: PV-9001); mouse goat serum (Zhongshan Jinqiao, ZLI-9022); DAB chromogenic kit (Zhongshan Jinqiao, batch No. K195225A ); reverse transcription kit (TaRaKa, catalog number RR037A); qPCR kit (Ta...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

PropertyMeasurementUnit
concentrationaaaaaaaaaa
concentrationaaaaaaaaaa
thicknessaaaaaaaaaa
Login to view more

Abstract

The invention discloses an application of CoQ10 in silicosis fibrosis resistance. The application is characterized by comprising the following steps: (1) setting a control group: selecting 24 male C57mice at SPF level and 6 yearlings, wherein the weight of the mice is at 20+ / -2g, firstly adaptively feeding for one week, and then randomly dividing into a control group, a model group and a treatment group; constructing a mice silicosis model by once instilling 0.1mL of SiO2 suspension into trachea for the model group and the treatment group, and installing the normal saline with the same volumeinto the control group through the same method; giving 0.1mL of CoQ10 every day after post-operation 48h of the treatment group, performing gastric perfusion, wherein the control group and the modelgroup are in independent feeding. The application disclosed by the invention has the advantages that the CoQ10 can reduce the silicosis fibrosis induced by the SiO2, and can lower the collagen, hydroxyproline and alpha-SMA expression; the action mechanism thereof can regulate the endogenous HMGCR expression in a feedback way and influence an oxidation respiratory chain, thereby providing a new perspective for the research of the subsequent silicosis treatment mechanism.

Description

technical field [0001] The invention relates to the technical field of medical engineering, in particular to a CoQ 10 Application in anti-silicosis fibrosis. Background technique [0002] At present, more than 850,000 cases of pneumoconiosis have been reported in my country, of which silicosis accounts for more than 50%. It is characterized by SiO 2 The particles are inhaled into the lungs, stimulating the lung tissue to start a self-repair mechanism and activating fibroblasts to produce collagen fibers. However, when the lung tissue is repeatedly or overstimulated, fibroblasts proliferate abnormally and secrete a large number of collagen fibers, resulting in excessive deposition of collagen in the lung interstitium, and fibrosis of the lung interstitium. Clinical treatment mainly focuses on bronchoalveolar lavage combined with anti-fibrosis and symptomatic treatment of complications. At the same time, comprehensive treatment strategies such as oxygen therapy and psycholo...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): G01N33/543G01N33/532G01N33/531G01N21/31C12Q1/6851
CPCC12Q1/6851G01N21/31G01N33/531G01N33/532G01N33/543C12Q2531/113C12Q2563/107C12Q2521/107
Inventor 刘志宏孙岳姜怡邓杨安宁蔺文轩王宇欣德小明
Owner NINGXIA MEDICAL UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products